2008 - Review: Low-molecular-weight heparin reduces risk for venous thromboembolism in adults with leg immobilization

Cosmi, Benilde
February 2009
ACP Journal Club;2/17/2009, Vol. 150 Issue 2, p2
Academic Journal
The article presents a research conducted by researcher M. Testroote and colleagues to find whether low-molecular-weight heparin (LMWH) reduces risk for venous thromboembolism in adults with leg immobilization or not. Studies selected compared LMWH with placebo or no thromboprophylaxis in adults with a leg injury requiring immobilization in a plaster cast or brace in an ambulatory setting.


Related Articles

  • Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility. Hull, Russell D.; Schellong, Sebastian M.; Tapson, Victor F.; Monreal, Manuel; Samama, Meyer-Michel; Nicol, Philippe; Vicaut, Eric; Turpie, Alexander G. G.; Yusen, Roger D. // Annals of Internal Medicine;7/6/2010, Vol. 153 Issue 1, p8 

    Background: Extended-duration low-molecular-weight heparin has been shown to prevent venous thromboembolism (VTE) in high-risk surgical patients. Objective: To evaluate the efficacy and safety of extendedduration enoxaparin thromboprophylaxis in acutely ill medical patients. Design: Randomized,...

  • Extended prophylaxis with idraparinux prevented recurrence of venous thromboembolism but increased risk for bleeding.  // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p20 

    The article presents a study which examines the effectiveness of idraparinux in treating patients with venous thromboembolism (VTE) who have completed six months of anticoagulant therapy. In patients with VTE who had completed six months of anticoagulant therapy, study shows that idraparinux...

  • Low-dose warfarin prevents recurrent thromboembolism. Plum, Mary-Beth Fennell // Journal of Family Practice;Aug2003, Vol. 52 Issue 8, p588 

    The article discusses research on the use of low-dose warfarin to prevent recurrent venous thromboembolism. Low-dose warfarin does not increase the risk of major bleeding when used for secondary prophylaxis. This should follow after three to twelve months of full-intensity warfarin after the...

  • Anaemia drug raises clot risk.  // GP: General Practitioner;2/29/2008, p14 

    The article reports that treating anemia in cancer patients with erythropoiesis-stimulating agents (ESAs) can increase blood clot risk as stated in the U.S. research findings. According to the author, anemia in cancer is often treated with erythropoeitin and darbepoetin but there have been...

  • Perioperative Management of Warfarin Therapy: To Bridge or Not to Bridge, That Is the Question. Douketis, James D. // Mayo Clinic Proceedings;Jun2008, Vol. 83 Issue 6, p628 

    The article presents the author's perspective on a study concerning the perioperative practice of administering bridging anticoagulation with subcutaneous low-molecular-weight heparin (LMWH). He remarks that the novel aspect of the study is the inclusion of a comparison group of patients who did...

  • Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. Takeshi Fuji; Takahiro Ochi; Shigeo Niwa; Satoru Fujita // Journal of Orthopaedic Science;Sep2008, Vol. 13 Issue 5, p442 

    Abstract Background  Enoxaparin is a low-molecular-weight heparin indicated in Europe and North America for the prevention of venous thromboembolism (VTE) in patients undergoing major orthopedic surgery. Registration trials of enoxaparin have been conducted primarily in Caucasian...

  • What are the best agents for preventing VTE in hospital patients?  // Journal of Family Practice;Oct2007, Vol. 56 Issue 10, p796 

    The article presents a meta-analysis which aims to determine which pharmacological agents are effective to prevent venous thromboembolism (VTE) in hospitalized medical patients. A literature search was performed to determine randomized trials that compared unfractionated heparin with control,...

  • INCIDENCE OF THROMBOCYTOPENIA IN HEPARINIZED PATIENTS. W. M., W. Haslindawani; M. Y., Shafini; M. N., N. Haslina; B., Rosnah; M., Rapiaah; I., Suhairi // Malaysian Journal of Medical Sciences;Jan2006 Supplement, Vol. 13, p218 

    INTRODUCTION : Heparin is widely used for thromboprophylaxis or treatment in many clinical situations, including cardiovascular surgery and invasive procedures, acute coronary syndromes, venous thromboembolism, atrial fibrillation, peripheral occlusive disease, dialysis and during extracorporeal...

  • THE PLACEBO: A READER. Lott, Rob // Health Affairs;Mar2014, Vol. 33 Issue 3, p518 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics